There are still no FDA-approved drugs that effectively target the most commonly mutated genes (KRAS, CDKN2A, TP53, and SMAD4) in PDAC, although Sotorasib (a KRAS-G12C inhibitor) was recently approved for advanced non-small cell lung cancer [1, 51]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.